arrow
P

Pierre-François Dequin

Research Centre for Respiratory Diseases
H指数:42
被引数:9,767

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acute kidney injury in severe Legionnaires’ Disease in ICU

重症军团菌病患者的急性肾损伤及入住ICU情况

2026-08-120
OAAI
Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial

使用简约机器学习模型量化肺炎和脓毒症中的免疫失调:一项跨照护设置的多队列分析以及对氢化可的松随机对照试验的再分析

2026-03-160
PRE
Renal replacement therapy in an intensive care unit: guidelines from the SRLF-GFRUP consensus conference

重症监护室中的肾脏替代治疗:SRLF-GFRUP 共识会议指南

2025-07-160
OA
Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial

联合应用多重PCR和血清降钙素原以减少社区获得性肺炎危重患者的抗生素暴露:MULTI-CAP随机对照试验

2025-07-150
PRE
Insulin therapy and blood glucose management in critically ill patients: a 1-day cross-sectional observational study in 69 French intensive care units
2023-06-174
OAAI
Hydrocortisone in Severe Community-Acquired Pneumonia
2023-05-25154
PRE
Outcomes of mild-to-moderate postresuscitation shock after non-shockable cardiac arrest and association with temperature management: a post hoc analysis of HYPERION trial data
2022-10-173
OAAI
Effects of mean arterial pressure target on mottling and arterial lactate normalization in patients with septic shock: a post hoc analysis of the SEPSISPAM randomized trial

平均动脉压目标对脓毒症休克患者斑驳和动脉乳酸正常化的影响: sepsipam随机试验的事后分析

2022-08-194
OAAI
Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study
2022-07-204
OA
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
2021-09-0155
OAAI